Please login to the form below

Not currently logged in
Email:
Password:

therapy watch

This page shows the latest therapy watch news and features for those working in and with pharma, biotech and healthcare.

New biosimilars group will tackle slow uptake in UK

New biosimilars group will tackle slow uptake in UK

Despite being around for several years in Europe, the awareness of biosimilars remains fairly low - with a survey carried out in 2014 by Therapy Watch finding just 8% of EU physicians

Latest news

  • Creating a brand identity for biosimilars Creating a brand identity for biosimilars

    Only 8 per cent of EU physicians spontaneously mentioned biosimilars as products in development in a recent survey by Therapy Watch, and only 35 per cent said they would definitely consider

More from news
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2015 Deal Watch October 2015

    More big pharma acquisitions on the horizon? We cannot close this month's Deal Watch without mentioning the reports filtering out near the end of October that Pfizer is back on

  • The evolving biosimilars market The evolving biosimilars market

    Although these key regulatory developments are expected to greatly facilitate the approval of biosimilars in the near future, recent research from Research Partnership's Therapy Watch revealed that only 47% of

  • Pharma deals in April 2015 Pharma deals in April 2015

    Watch this space!  . Gene Therapy. After years of promise and failing to deliver, gene therapy companies are back in favour. ... No deal terms were disclosed. The initial development plan will look at the combination therapy as a potential treatment for

  • Deal Watch table for December 2014 Deal Watch table for December 2014

    Licence - amended agreement. †300. Spark Therapeutics / Pfizer. Multiple haemophilia B gene therapy products (preclinical). ... Gene therapy collaboration. 280. Xencor / Novo Nordisk. XmAb technologies, inc bispecific and immune inhibitor technologies,

  • Biosimilars: friend or foe for healthcare systems? Biosimilars: friend or foe for healthcare systems?

    As the Therapy Watch data indicates, though, many believe the decision will ultimately be taken out of their hands. ... Fleetwood is director of Therapy Watch at the Research Partnership and can be contacted on tel: 44 208 0695049 or email her.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

  • Research Partnership appoints new directors Research Partnership appoints new directors

    th. anniversary.”. “Having worked with Anne previously as a client of our syndicated market-tracking tool Therapy Watch, it’s great to now be able to welcome her to our

  • Helen Parfitt joins Research Partnership Helen Parfitt joins Research Partnership

    She takes on role as head of its Therapy Watch market tracking tool. ... I believe she will be a strong asset to the Therapy Watch team and we look forward to her contributing to its continued growth and development.”.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 14 fully matching, plus 16 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....

Infographics